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Trisomy 21Down syndrome (DS) is the most common genetic cause of intellectual disability in children, and the num-
ber of adults with DS reaching old age is increasing. By the age of 40 years, virtually all people with DS have
sufﬁcient neuropathology for a postmortem diagnosis of Alzheimer disease (AD). Trisomy 21 in DS leads to
an overexpression of many proteins, of which at least two are involved in oxidative stress and AD: super-
oxide dismutase 1 (SOD1) and amyloid precursor protein (APP). In this study, we tested the hypothesis that
DS brains with neuropathological hallmarks of AD have more oxidative and nitrosative stress than those
with DS but without signiﬁcant AD pathology, as compared with similarly aged-matched non-DS controls.
The frontal cortex was examined in 70 autopsy cases (n=29 control and n=41 DS). By ELISA, we quantiﬁed
soluble and insoluble Aβ40 and Aβ42, as well as oligomers. Oxidative and nitrosative stress levels (protein car-
bonyls, 4-hydroxy-2-trans-nonenal (HNE)-bound proteins, and 3-nitrotyrosine) were measured by slot-blot.
We found that soluble and insoluble amyloid beta peptide (Aβ) and oligomers increase as a function of age in
DS frontal cortex. Of the oxidative stress markers, HNE-bound proteins were increased overall in DS. Protein
carbonyls were correlated with Aβ40 levels. These results suggest that oxidative damage, but not nitrosative
stress, may contribute to the onset and progression of AD pathogenesis in DS. Conceivably, treatment with
antioxidants may provide a point of intervention to slow pathological alterations in DS.ent of Chemistry, Center of,
ging, University of Kentucky,
and Biomedical Pharmacology,
ky, Lexington, KY 40536, USA.
, Elizabeth.Head@uky.edu
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
One of the most common genetic abnormalities in live-born chil-
dren in the United States (1 in 700–1000) is Down syndrome (DS)
[20]. DS is linked to an extra copy of chromosome 21 [42]. In addition
to intellectual disability, children often have cardiac and gastrointes-
tinal congenital malformations, various types of leukemia, growth
retardation, immune disorders and other clinical pathologies [66].A key concern in adults with DS is an increased vulnerability to the
development of Alzheimer disease (AD), which typically has an age
of onset between 40 and 60 years [71].
A link between DS and AD has been established [4, 12, 47, 48]. Vir-
tually all DS adults over the age of 40 years show neuropathological
hallmarks of AD, including senile plaques (SPs) and neuroﬁbrillary
tangles (NFTs) [30, 53, 81]. SPs are primarily composed of amyloid
beta peptide (Aβ) produced via sequential cleavage of the amyloid
precursor protein (APP) by beta- and gamma-secretase [73]. Several
peptides of varying lengths are produced, but the most actively stud-
ied are the 42 amino acid fragment (Aβ42) and the more soluble 40
amino acid peptide (Aβ40) [72]. Aβ42 shows a higher propensity to
adopt neurotoxic conformations, including oligomers [46, 61]. Oligo-
mers of Aβ have been increasingly implicated in the initiation and
pathogenesis of AD, while monomeric forms of Aβmay be less harm-
ful [23, 78]. In DS, the accumulation of Aβ42 in brain can be observed
as young as between 8 and 12 years of age [43, 45]. The extent of
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NFTs developing after SPs [52, 81]. Deposits of Aβ in DS are ﬁrst
seen in the frontal and entorhinal cortex and spread to other cor-
tical regions and layers with increasing age [3]. Interestingly, the
incidence of dementia typically does not increase until adults
with DS are over the age of 50 years [39, 48, 69, 75], suggesting a
~10 year prodromal phase where clinical signs are minimal or
not detectable.
Similar to AD ([2, 29, 54, 74]; Butterﬁeld et al.), Aβ accumulation
in DS is associated with enhanced formation of reactive oxygen spe-
cies (ROS) in neurons leading to premature neuronal dysfunction
and death as a consequence of increased oxidative stress [11, 37,
50]. Interestingly, intracellular Aβ accumulation is observed early in
DS, prior to the accumulation of extracellular Aβ deposits [18, 19].
Subsequently high molecular weight aggregates of Aβ may accumu-
late, enhancing the deposition of plaques [27, 38] and ROS production
[6]. Moreover, of many genes overexpressed due to trisomy 21, sever-
al are particularly relevant for the development of AD in DS. Among
these, APP and cytoplasmic superoxide dismutase (Cu2+/Zn2+;
SOD1) play a pivotal role in the regulation of oxidative and nitrosative
stress levels [17, 68].
To characterize age- and AD-associated changes in oxidative and
nitrosative stress in the frontal cortex from DS autopsy cases, we
quantiﬁed two markers of protein oxidation (protein carbonyls
[PCs] and 3-nitrotyrosine [3-NT]) and a marker of protein modiﬁca-
tion that is a lipid peroxidation product (4-hydroxy-2-trans-nonenal
[HNE]). In these samples, we also examined the levels of Aβ40 and
Aβ42 and Aβ oligomers. We hypothesized that oxidative damage
would be higher overall in DS as compared to non-DS, but further ex-
acerbated with the development of AD neuropathology. In addition,
we hypothesized that the extent of oxidative and nitrosative damage
would be associated with levels of age-associated Aβ accumulation in
DS brain.2. Materials and methods
2.1. Subjects
DS and young or non-demented older control cases were
obtained from the University of California-Irvine-ADRC Brain Tissue
Repository, the Eunice Kennedy Shriver NICHD Brain and Tissue
Bank for Developmental Disorders, and the University of Kentucky
ADC. Table 1 shows the characteristics of the included cases. DS
cases were divided into two groups, with or without sufﬁcient pa-
thology for a neuropathology diagnosis of AD. All cases with both
DS and AD were over the age of 40 years. Thus for the current
study, controls were split into two groups, either less than or equal
to 40 years or older than 40 years at death. The post mortem interval
(PMI) was different across groups, with the AD group overall having
a lower PMI (F(3,66)=7.3 pb0.0005). A subset of these autopsy
cases was used in a previous experiment measuring insoluble Aβ
as a function of age in DS [56]. In the current study, additional
cases were included, soluble Aβ was measured and the extent of
oligomer accumulation was quantiﬁed.Table 1
Case demographics.
Group n Gender (M/F) Age (SEM) PMI (SEM)
Young control (YC) 13 8/5 17.8 (3.7) 16.2 (1.9)
Old control (OC) 16 7/9 50.8 (2.2) 14.3 (2.0)
DS 13 7/6 27.2 (5.1) 16.0 (1.7)
DS+AD 28 12/16 53.8 (2.5) 6.91 (1.2)2.2. Sample preparation for oxidative stress measures
Brain tissue (frontal cortex) from non-DS controls, DS, and DS
with AD were thawed in lysis buffer (pH 7.4) containing 320 mM
sucrose, 1% of 1.0 M Tris–HCl (pH=8.8), 0.098 mM MgCl2,
0.076 mM EDTA, proteinase inhibitors leupeptin (0.5 mg/ml), pep-
statin (0.7 μg/ml), aprotinin (0.5 mg/ml), and phosphatase inhibi-
tor cocktail (Sigma Aldrich, St. Louis, MO). The brains were
homogenized by 20 passes of a Wheaton tissue homogenizer, and
the resulting homogenate was centrifuged at 14,000×g for 10 min
to remove cellular debris. The supernatant was extracted to deter-
mine the total protein concentration by the BCA method (Pierce,
Rockford, IL).
2.3. Measurement of protein carbonyls (PCs)
Five microliters of frontal cortex homogenate were derivatized
with 10 μl of 10 mM 2,4-dinitrophenylhydrazine (DNPH) (OxyBlot™
Protein Oxidation Detection Kit, Chemicon-Millipore, Billerica, MA)
in the presence of 5 μl of 10% sodium dodecyl sulfate (SDS) for
20 min at room temperature (25 °C). The samples were then neutral-
ized with 7.5 μl of 2 M Tris in 30% glycerol. Protein samples (250 ng)
were then loaded in each well on a nitrocellulose membrane with a
slot-blot apparatus under vacuum. The membrane was blocked for
2 h with a solution of 3% (w/v) bovine serum albumin in PBS contain-
ing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20. Membranes
were incubated with rabbit polyclonal anti-DNP antibody (1:100
dilution, OxyBlot™ Protein Oxidation Detection Kit) for 2 h at room
temperature. After washingwith PBS, membranes were further incu-
bated with alkaline phosphatase-conjugated goat anti-rabbit sec-
ondary antibody (1:5000; Sigma Aldrich, St. Louis, MO) for 1 h at
room temperature. Membranes were then washed with PBS three
times for 5 min and developed using 5-bromo-4-chloro-3-indolyl-
phosphate/nitroblue tetrazolium (BCIP/NBT) color developing reagent
for alkaline phosphatase activity (Sigma Aldrich). Blots were dried and
scanned to TIF format using Adobe Photoshop on a Canoscan 8800F
(Canon, Lake Success, NY). The images were quantiﬁed with Image
Quant TL 1D version 7.0 software (GE Healthcare, Fairﬁeld, CT).
2.4. Measurement of protein-bound 4-hydroxy-2-trans-nonenal
(HNE-bound protein)
For the analysis of HNE-bound protein levels, 10 μl of frontal cortex
homogenate were incubated with 10 μl of Laemmli buffer containing
0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol. The
resulting samples (250 ng per well) were loaded onto a nitrocellulose
membrane with a slot-blot apparatus under vacuum pressure. The
membrane was blocked as described above for 2 h and incubated
with a rabbit polyclonal anti-4-hydroxynonenal antibody (1:3000;
Alpha Diagnostics, San Antonio, TX) for 2 h at room temperature.
Membranes were washed and incubated with anti-rabbit IgG alkaline
phosphatase secondary antibody (1:5000; Sigma-Aldrich) for 1 h at
room temperature. Membranes were then processed and quantiﬁed
as described above.
2.5. Measurement of 3-nitrotyrosine (3-NT)
3-NT content was determined immunochemically as previously
described [16]. Brieﬂy, 5 μl of frontal cortex homogenate were in-
cubated with Laemmli sample buffer in a 1:2 ratio (0.125 M Trizma
base, pH 6.8, 4% SDS, 20% glycerol) for 20 min. Protein (250 ng per
well) was then loaded onto the nitrocellulose membrane using
the slot-blot apparatus as described above. Membranes were in-
cubated with rabbit anti-nitrotyrosine antibody (1:1000; Sigma-
Aldrich) for 2 h at room temperature. Membranes were then
washed and incubated with alkaline phosphatase-linked anti-rabbit
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temperature. Membranes were then processed and quantiﬁed as
described above.
2.6. Aβ ELISAs
Aβ was extracted from tissue measured as previously described
[5]. Brieﬂy, frozen cortical samples were extracted sequentially in
ice cold phosphate buffered saline (PBS, pH 7.4) with a complete pro-
tease inhibitor cocktail (PIC) (Amresco, Solon, OH) and centrifuged at
20,800×g for 30 min. at 4 °C. Following centrifugation, the superna-
tant was collected and the pellets were sonicated (10×0.5 s pulses
at 100 W, Sonic Dismembrator, Fisher Scientiﬁc, Pittsburgh, PA) in
2% SDS with PIC and centrifuged at 20,800×g for 30 min. at 14 °C.
The supernatant was again collected and the remaining pellets were
sonicated in 70% formic acid (FA), followed by centrifugation at
20,800×g for 1 h at 4 °C.
FA-extracted material was initially neutralized by a 1:20 dilution
in TP buffer (1 M Tris base, 0.5 M Na2HPO4), followed by a further di-
lution as needed (1:100 to 1:400) in Antigen Capture buffer (AC)
(20 mM Na3PO4, 0.4% Block Ace (AbD Serotec), 0.05% NaN3, 2 mM
EDTA, 0.4 M NaCl, 0.2% BSA, 0.05% CHAPS, pH 7). SDS soluble fractions
were diluted (1:20) in AC buffer alone. PBS fractions were diluted 1:4
in AC buffer alone.
Aβ was measured in tissue samples using a standard, well-
characterized two-site sandwich ELISA as described previously [47].
Brieﬂy, an Immulon 4HBX plate was coated with 0.5 μg antibody
per well, incubated overnight at 4 °C, and blocked with a solution of
Synblock (AbD Serotec, Raleigh, NC), as per themanufacturer's instruc-
tions. Antigen capture was performed using monoclonal antibody
Ab9 (against Human Aβ1–16). Antigen detection was performed
using biotinylated antibodies 13.1.1 (speciﬁc for Aβ40) and 12F4
(speciﬁc for Aβ42; Covance, Princeton, NJ).
A peptide standard curve of Aβ was run on the same plate for
comparison, and standards and samples were run at least in dupli-
cate; Aβ values were determined by interpolation relative to the stan-
dard curve. Plates were washed between steps with standard PBS
containing 0.05% Tween-20 (2–4×) followed by PBS (2–4×). Plates
were developed with TMB reagent (KPL, Inc., Gaitherburg, MD),
stopped with 6% o-phosphoric acid, and read at 450 nm using a multi-
well plate reader (BioTek, Winooski, VT).
2.7. Oligomer assay
Aβ oligomers from the SDS-soluble fraction were measured using a
single-site sandwich ELISA as described above, except the same anti-
body (4G8; Covance, Princeton, NJ) was used for capture and detection.
SDS samples were diluted 1:50 in AC buffer. Synthetic Aβ42 oligomers
were used to prepare a standard curve; oligomeric Aβ values
were determined by interpolation relative to the standard curve.
2.8. Statistical analysis
A univariate analysis of covariance (ANCOVA)with PMI as the covar-
iatewas used to compare groups on different outcomemeasures reﬂect-
ing oxidative stress. In these analyses, we compared DS v. non-DS.
Further, we placed DS cases into two groups, either having insufﬁcient
pathology for a diagnosis of AD or having sufﬁcient neuropathology
for a diagnosis of AD. Since the majority of DS cases with AD neuropa-
thology were over 40 years, the control cases were categorized as either
≤40 or >40 years old. For comparison of two groups, independent
t-tests were used. Spearman rank correlations were calculated to test
the association between age and oxidative damage, as well as oxidative
damage and Aβ. All statistics were calculated using PASW (IBM,
Chicago, IL) and evaluated using a p-value of b0.05.3. Results
3.1. Effect of PMI and gender on oxidative and nitrosative stress marker
levels in the brain from control, DS, and DS with AD subjects
We ﬁrst determined whether PMI was a signiﬁcant contributor to
the various measures of oxidative damage, given that DS with AD
cases overall had shorter PMIs. The correlation between PMI and
PCs (r=−0.34, p=0.004), 3-NT (r=−0.015, p=0.90) and HNE-
bound proteins (r=−0.10, p=0.41) show that PCs are negatively
correlated with PMI. Thus, for subsequent analyses, PMI was included
as a covariate. We then examined whether gender (n=34 male and
n=35 female) was a contributor to the outcomes. All samples were
combined for this analysis and an independent t-test did not show
gender effects on PCs (t (67)=0.58, p=0.57), 3-NT (t (67)=
−0.42, p=0.68), or HNE-bound proteins (t (67)=0.0.54, p=0.59).
3.2. Oxidative and nitrosative marker levels in control, DS, and DS with
AD subjects
We tested the hypothesis that oxidative damage would be higher
in DS overall relative to controls and higher still in DS cases with AD
neuropathology. An ANCOVAwas used with genotype (DS or Control)
and age group (≤40 years or >40 years) as factors and PMI as a co-
variate. No signiﬁcant differences in PC were noted by genotype
(F(1,69)=0.15, p=0.70), age group (F(1,69)=0.19, p=0.66), or
interaction between genotype and age (F(1,69)=0.25 p=0.62)
(Fig. 1A), although there was a trend towards higher PC in DS
cases with AD. Similarly, no signiﬁcant differences in 3-NT were ob-
served by genotype (F(1,69)=0.19 p=0.7), age group (F(1,69)=
1.3 p=0.3), or interaction between genotype and age group
(F(1,69)=0.4 p=0.5) (Fig. 1B). Interestingly, HNE-bound proteins
were signiﬁcantly higher overall in DS cases≤40 years of age
(F(1,69)=5.6 p=0.02), but no signiﬁcant differences were noted
by age group (F(1,69)=0.02 p=0.9) or interaction between age
and genotype (F(1,69)=1.59 p=0.2; Fig. 1C).
3.3. Aβ and oligomer accumulation in DS brain
To determine if soluble or insoluble forms of Aβ as well as oligo-
mers were differentially higher in individuals with DS±AD relative
to controls, a univariate analysis of variance was conducted. For virtu-
ally all Aβ outcome measures, there was individual variability, partic-
ularly in the older DS brains with signiﬁcant AD neuropathology.
PBS-soluble Aβ40 was signiﬁcantly higher in individuals>40 years
old (F(1,69)=4.21 p=0.044), but was not signiﬁcant by genotype
(F(1,69)=2.91 p=0.09) or interaction between age and genotype
(F(1,69)=2.90 p=0.093; Fig. 2A). SDS-extracted Aβ40 was signiﬁ-
cantly higher in DS (F(1,69)=4.79 p=0.032) and in cases>40 years
old (F(1,69)=4.83 p=0.032). The interaction between the presence
of DS and age>40 years was also signiﬁcant (F(1,69)=4.81
p=0.032), with older DS individuals having the highest average
amounts of SDS-extracted Aβ40 (Fig. 2B). FA-extracted Aβ40 was sig-
niﬁcantly higher in individuals with DS (F(1,69)=3.9 p=0.05) and
in individuals>40 years old (F(1,69)=3.92 p=0.05). Further, as
with SDS-extracted Aβ40, FA-extracted Aβ40 was highest in adults
with DS over the age of 40 years (F(1,69)=3.91 p=0.05) (Fig. 2C).
PBS-extracted Aβ42 did not differ across genotype groups or
age groups; however, there was signiﬁcant individual variability
(Fig. 2D). Similarly, older individuals had lower PBS Aβ42 than youn-
ger individuals (F(1,67)=3.76 p=0.57), regardless of genotype
(Fig. 3D). The interaction between genotype and age group was not
signiﬁcant. SDS-extracted Aβ42 was signiﬁcantly higher overall in
individuals with DS (F(1,69)=10.89 p=0.002) and in individuals>
40 years old (F(1,69)=8.4 p=0.005). Further, adults with DS over
Fig. 1. Levels of oxidative and nitrosative stress markers in control, DS, and DS with AD cases. Protein was extracted from frontal cortex and loaded on nitrocellulose membranes in a
slot-blot apparatus. Membranes were probed with either anti-DNP protein adducts polyclonal antibody (Fig. 1A), anti-nitrotyrosine polyclonal antibody (Fig. 1B), or anti-HNE-
bound protein polyclonal antibody (Fig. 1C). Data are expressed as mean±SEM (*p=0.02).
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all (F(1,69)=8.23 p=0.006; Fig. 2E).
The effect of age on FA-extracted Aβ42 was similar to that of SDS-
extracted Aβ42, with cases over 40 years having signiﬁcantly higher
levels of Aβ overall (F(1,69)=9.08 p=0.004). Although DS cases
overall had higher levels of FA-extracted Aβ relative to controls,
this difference only approached statistical signiﬁcance due to large
individual differences (F(1,69)=3.4 p=0.069) and the interaction
between genotype and age was not signiﬁcant (F(1,69)=3.22
p=0.078) (Fig. 3F). The lack of signiﬁcance for the interaction
term was primarily due to one individual without DS over the age
of 40 years with a substantially higher amount of FA-extracted
Aβ42 than all the other cases (including DS). When this case was
removed, FA-extracted Aβ42 was signiﬁcantly different by both ge-
notypes (F(1,68)=7.9 p=0.006) and the interaction was alsoFig. 2. Soluble and insoluble Aβ40 and Aβ42 as a function of genotype and age group. PBS-,
SDS- and FA-extracted Aβ40 were also signiﬁcantly higher in DS (B and C) and highest in
extracted Aβ42 was higher overall with age, with DS and DS with AD cases showing the h
DS (F). Bars represent mean±SEM. Closed circles indicate individual data points.signiﬁcant (F(1,68)=7.58 p=0.008), indicating that individuals
with DS over the age of 40 years had higher levels of FA-extracted
Aβ42 overall (Fig. 2F).
As shown in Fig. 4, all measures of Aβ except PBS-extracted Aβ42
were signiﬁcantly correlated with age in DS cases (Table 2 shows cor-
relation co-efﬁcients). Interestingly, in control cases, SDS-extracted
Aβ40 and Aβ42 were both correlated with age (Fig. 3).
Oligomeric Aβ accumulation was not signiﬁcantly different for ge-
notype (F(1,69)=1.64 p=0.21), although and the main effect of age
approached signiﬁcance (F(1,69)=2.96 p=0.09). The interaction
between genotype and age was signiﬁcant (F(1,69)=6.08 p=0.02),
which was a result of individuals with DS over the age of 40 years
having signiﬁcantly higher levels of Aβ oligomers (Fig. 4A). The ex-
tent of PBS-extracted Aβ oligomers in DS (r=0.37 p=0.018) but
not in control cases was correlated with age (Fig. 4B).SDS-, and FA-extracted Aβ40 increased with age in both DS and controls (A, B and C).
DS with AD. No genotype or age effects were noted for PBS-extracted Aβ42 (D). SDS-
ighest levels overall (E). FA-extracted Aβ42 was higher in older cases with or without
Fig. 3. Correlations between age and Aβ as a function of genotype. PBS-, SDS-, and FA-extracted Aβ40 increased with age in DS (A, B and C). However, in control cases, only SDS-
extracted Aβ40 increased with age. SDS- and FA-extracted Aβ40 also increased with age in DS (E and F), although PBS-extracted Aβ42 did not (D). As with SDS-extracted Aβ40,
Aβ42 increased with age in control cases, although levels were not as high as in those with DS (E).
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In all Aβ measures, the DS cases and particularly those over
the age of 40 years showed signiﬁcant individual variability. Thus,
we hypothesized that individual Aβmeasures may reﬂect differences
in the level of oxidative damage. A partial correlation co-efﬁcient that
controlled for PMI was calculated between Aβ measures and mea-
sures of oxidative damage. The amount of oligomeric Aβ was notcorrelated with PCs (r=0.17 p=0.16), NT (r=−0.07 p=0.55) or
HNE (r=−0.097 p=0.43). Similarly, there were no correlations be-
tween any measure of Aβ42 and the extent of PCs (PBS Aβ42 r=
−0.14 p=0.27; SDS Aβ42 r=0.02 p=0.89; FA Aβ42 r=0.13
p=0.31), HNE (PBS Aβ42 r=−0.03 p=0.0.83; SDS Aβ42 r=0.04
p=0.77; FA Aβ42 r=−0.10 p=0.43), or 3-NT (PBS Aβ42 r=
−0.18 p=0.38; SDS Aβ42 r=−0.07 p=0.58; FA Aβ42 r=−0.14
p=0.91). There was a trend towards PBS-extracted Aβ40 being
Fig. 4. Aβ Oligomer accumulation with age and DS and correlations between oxidative damage and Aβ. Oligomer accumulation was signiﬁcantly higher in DS cases over the age of
40 years with signiﬁcant AD neuropathology (A). Further, oligomers increased as a function of age in DS but not in control cases (B). Higher levels of SDS-extracted Aβ40 (D) and
FA-extracted Aβ40 (E) were signiﬁcantly correlated with higher levels of PCs. A similar trend was observed between PBS-extracted Aβ40 and PCs (C). Bars represent mean±SEM.
Closed circles indicate individual data points.
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(r=0.310 p=0.058 n=36) (Fig. 4C). SDS- (r=0.369 p=0.023
n=36) and FA- (r=0.39 p=0.016 p=36) extracted Aβ40 were cor-
related with signiﬁcantly higher PC accumulation, but were not corre-
lated with either HNE or 3-NT levels (Fig. 4D, E).
4. Discussion
An imbalance between pro-oxidant stimuli and cellular antioxi-
dant activity may lead to increased oxidative stress levels that may
have an important role in the development of AD neuropathology
in DS [9, 11, 37]. Involvement of oxidative and nitrosative stress-Table 2
Correlations between Aβ and age in DS and controls.






Control 29 0.32 0.37⁎ 0.22
DS 40 0.37⁎ 0.38⁎ 0.37⁎






Control 29 0.26 0.40⁎ 0.31
DS 40 −0.08 0.37⁎ 0.42⁎
⁎ pb .05.induced neuronal damage is a well-established feature during the
development of AD [14, 17, 74]. In the current study, we provided
new evidence of higher levels of oxidative damage in brains from
individuals with DS, although measures of oxidative damage were
not increased further with AD pathology. The frontal cortex of DS
subjects had signiﬁcantly increased HNE-bound proteins levels, a
sensitive marker of lipid peroxidation, compared to non-DS con-
trols. Lipid peroxidation leads to various aldehydic products, with
4-hydroxy-2-nonenal (HNE) being one of the most abundant
[76]. HNE is a highly reactive alkenal responsible for the damaging
effects of oxidative stress and linked to neurodegenerative diseases
such as AD [7, 14, 65].
This study extends earlier studies demonstrating that lipoperoxi-
dation is enhanced in prenatal DS brains compared to non-DS con-
trols [8, 59]. Pratico et al. also demonstrated that another marker of
lipid peroxidation, 8,12-iso-iPF2α-VI, was signiﬁcantly increased in
the urine of young subjects with DS, as compared to age-matched
controls [63]. Furthermore, cortical neurons cultured from prenatal
DS cases exhibited the intracellular accumulation of ROS and in-
creased lipid peroxidation, leading to neuronal apoptosis [11]. A re-
cent study showed that amniotic ﬂuid from mothers carrying DS
fetuses had signiﬁcantly elevated markers of oxidation [60]. HNE-
bound proteins were also present in the embryonic brains of Ts1Cje
mice, a transgenic animal model of DS [34]. In combination, these
data suggest that lipid peroxidation is an early and possibly chronic
event in DS.
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pression of one of the key enzymes in the regulation of oxidative
stress, SOD1 [21, 24]. Levels of SOD1 in cells from DS patients are ap-
proximately 50% greater than normal [25]. In general, SOD1 is respon-
sible for converting superoxide radical into hydrogen peroxide, which
is subsequently neutralized by glutathione peroxidase or catalase
[32]. If catalase or glutathione peroxidase activity in DS brains is not
able to compensate for the increased superoxide dismutase level
and activity, hydrogen peroxide may accumulate, leading to increased
oxidative damage [35, 63]. Consistent with this hypothesis, gene
transfection of SOD1 into two different cell lines leads to increased
lipid peroxidation, elevated PCs, and a trend to toward increased
levels of 8-hydroxyguanine and 3-NT [41]. However, in the current
study, 3-NT levels, a marker of protein nitration and nitrosative stress,
was neither higher in DS nor further increased with AD neuropathol-
ogy. Surprisingly, PCs, a marker of protein oxidation that typically
shows robust increases in AD in the general population [2], showed
a trend towards increasing levels in DS with AD neuropathology but
did not reach statistical signiﬁcance, most likely due to individual var-
iability in DS cases.
The gene for APP, a key protein involved in AD, is located on chro-
mosome 21 [80]. The overexpression of APP in DS is associated with
increased concentrations of Aβ in the brains of these individuals,
and Aβ neuropathology has been well characterized in DS [30, 52,
81]. Aβ plaques have been observed as young as 8 years of age and
consistently accumulate after 30 years of age [43, 45]. The prevalence
of dementia, however, does not increase substantially until after
50 years of age and some individuals with DS remain dementia-free
[71, 75]. In an extension of previous work [56], we now show that
both soluble and insoluble Aβ40 and Aβ42 in the frontal cortex in-
crease with age in DS. The one exception appears to be a PBS-soluble
form of Aβ42 peptide, which did not show a consistent age or geno-
type association.
We provide novel information regarding oligomer accumulation
in DS as a function of age and genotype in a large autopsy cohort.
There were no signiﬁcant group mean differences between cases
with or without DS. However, individuals with DS over the age of
40 years with AD neuropathology have signiﬁcantly higher levels of
Aβ oligomers. Further, age and oligomer accumulation were signiﬁ-
cantly correlated in DS but not controls. These data conﬁrm a previ-
ous case report in which immunohistochemistry was performed on
the brain of a 46 year old subject with DS and AD, in which plaque-
associated oligomer deposits were seen in the entorhinal and frontal
cortex [49]. In addition, using an antibody that recognizes Aβ ﬁbrils
and soluble ﬁbrillar oligomers, we previously demonstrated that DS
individuals show an early age of ﬁbrillar Aβ neuropathology onset
in hippocampus and midfrontal gyrus, as compared to aged non-DS
individuals [67]. In addition, age-dependent accumulation of Aβ ﬁbrils
increased as a function of age in DS, which was absent in non-DS
controls [67].
Once Aβ is cleaved from APP, it may appear ﬁrst as a soluble iso-
form. Soluble isoforms of Aβ, including oligomers, protoﬁbrils, and
Aβ-derived diffusible ligands may initially accumulate inside neu-
rons and may be more important in causing neuronal dysfunction
than extracellular Aβ. These different assembly states of soluble Aβ
show different toxicities [22, 44]. For example, Aβ oligomers are
toxic to neurons both in vitro [22, 40] and in vivo [44, 78]. Further,
oligomeric Aβ may cause mitochondrial dysfunction through inter-
actions with dynamin-related protein 1, exacerbating the oxidative
defect in DS [51]. Therefore, Aβ oligomers may be important in caus-
ing neuronal dysfunction before neuronal loss occurs during aging in
DS [36]. By studying the brains of individuals with DS that came to
autopsy at a wide range of ages, it may be possible to determine
temporal events associated with soluble and insoluble Aβ, oligomers,
and intracellular Aβ that may precede the onset of clinical signs of
dementia.Aβ is associated with oxidative stress in vitro and in vivo [13, 15, 28].
The presence of Aβ deposits in DS brain may be a critical factor in
the generation of oxidative stress, similar to AD patients in the general
population [29, 54, 74]. In turn, neuronal oxidative stress may lead to
enhanced Aβ production [58, 62]. Indeed, a previous report of oxidized
Aβ in the frontal and entorhinal cortex from AD and DS cases showed
that this modiﬁcation was associated with neuritic plaques, suggesting
that oxidation of Aβ is an important event in plaque biogenesis [27].
Therefore, increased oxidative damage in DS may affect a variety of
pathways.
Oxidative damagemay lead to enhanced Aβ production [58, 62, 64]
and vice versa, higher levels of Aβ may exacerbate ongoing oxidative
damage [6, 31, 77]. In DS, abnormal APP processing may result from
increases in reactive oxygen species production due to mitochondrial
dysfunction [10]. Increased oxidative damage reﬂecting overexpres-
sion of SOD1 in DS may also impact degradation of Aβ, as enzymes
responsible for Aβ degradation and clearance may themselves be
vulnerable to oxidative damage. A rise in oxidized neprilysin, an en-
zyme responsible for degrading Aβ, in AD brain may provide one
mechanism underlying the accumulation of extracellular Aβ [79].
The data reported in this study demonstrate a selective positive
correlation between one marker of oxidative stress (PCs) and the
levels of Aβ40 peptide. Although Aβ42 is generally regarded as the
more toxic of the two peptides, Aβ40 has been shown to be neurotox-
ic in neuronal cultures [1, 26]. Furthermore, Aβ40 may exert neuro-
toxic properties on neuronal progenitor cells, impairing the survival
and differentiation of these cells by generating oxidative damage
[55]. Lastly, Aβ40 ﬁbrils are able to directly induce speciﬁc nitrosative
and oxidative modiﬁcations such as oxidation, glycation, and 3-
nitrotyrosination in cell proteins [33]. However, it is surprising that
we did not see an association between Aβ42 and oxidative damage.
Indeed, Aβ42 is capable of causing oxidative stress through free rad-
ical reactions [82]. One possible explanation of these data could be
related to the amount of Aβ42 and Aβ40 measured in the frontal
cortex. The amount of Aβ40 is consistently higher than Aβ42 in
the frontal cortex in DS, particularly in DS with AD. Therefore, we
hypothesize that the oxidative stress observed in DS brains may be
more strongly associated with Aβ40 than Aβ42. Interestingly, in-
creasing plasma Aβ40 levels in adults with DS is associated with
onset of dementia [70]. Interestingly, prior to Aβ deposition in DS,
oxidized DNA/RNA rises with age but once Aβ42 is deposited in DS
temporal cortex there appears to be a decrease in the level of oxi-
dized DNA/RNA [57, 58]. It is possible that Aβ might serve an anti-
oxidant role in DS and is consistent with the lack of further increase
in oxidative damage noted in the current study in individuals with
both DS and AD. We note, however, that both measures of oxidative
damage and Aβ were by immunohistochemical methods whereas
the current study used bulk protein measures.
In summary, we demonstrate that oxidative stress, but not nitro-
sative stress, is present in DS brain. Speciﬁcally, markers of oxidative
stress are signiﬁcantly correlated with Aβ40 monomer levels. Lipid
peroxidation appears to be an early event occurring in DS individuals,
as it is present in both younger and older cases. Increased oxidative
stress may leave the DS brain vulnerable to subsequent AD neuropa-
thology. The oxidative and nitrosative protein modiﬁcations analyzed
in the frontal cortex of DS, DS with AD, and control individuals can
lead to dysfunctional proteins. Future experiments should focus on
determining which proteins are modiﬁed by oxidative stress in DS.
We also note that our measures represent bulk determinations of
proteins, and not only will neuronal and glial cell populations contrib-
ute to these results but importantly, vascular cells will also contribute
signiﬁcantly. Proteomics analysis may be a useful approach for this
type of investigation, resulting in a better understanding of which
biological mechanisms are involved in the onset and progression of
AD in DS, which may then provide useful information for clinical tri-
als in DS.
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